Previous 10 | Next 10 |
The following healthcare companies have filed prospectuses for mixed shelf offerings: More news on: Genprex, Inc., Syros Pharmaceuticals, Inc., ChromaDex Corporation, Healthcare stocks news, , Read more ...
EMERYVILLE, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the introduction in the U.S. of a new suite of materials to better support and celebrate siblings of those living with Drave...
Many investors have serious reservations about dipping their toes in the cannabis industry. After all, pot companies have generally delivered mediocre financial results over the past few quarters, and many have seen their shares drop significantly. The ongoing COVID-19 pandemic didn't help the s...
Zogenix ( ZGNX ) pulled back hard in late February of this year, touching a three-year low on Fintepla® Phase 3 data for Lennox-Gastaut syndrome, "LGS", which met the trial's objectives , but were not as good as some expected given the drug's impressive efficacy in Dravet syndrome,"DS". ...
Rational for a Copycat Strategy Research from Barclay and Novus published in October 2019 found that a stock selection copycat strategy that combines conviction and consensus of fund managers that have longer-term views outperformed the S&P 500 by 3.80% on average annually from Q1 2004...
EMERYVILLE, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the U.S. launch of Shine Forward with Dravet , a unique set of online tips, tools, and advice from Dravet families designed ...
Image source: The Motley Fool. Zogenix Inc (NASDAQ: ZGNX) Q1 2020 Earnings Call May 6, 2020 , 8:30 p.m. ET Operator Continue reading
EMERYVILLE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Wednesday, May 13, 2020, at the BofA Securities 2020 Virt...
Zogenix, Inc. (ZGNX) Q1 2020 Earnings Conference Call May 05, 2020 4:30 PM ET Company Participants Brian Ritchie - Lifesci Advisors Stephen Farr - Chief Executive Officer Ashish Sagrolikar - Chief Commercial Officer Michael Smith - Chief Financial Officer Conference Call Par...
Zogenix (NASDAQ: ZGNX ): Q1 GAAP EPS of -$0.54 beats by $0.54 . Revenue of $1.25M beats by $0.87M . Press Release More news on: Zogenix, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. Th...
Zogenix Inc. (NASDAQ:ZGNX) traded today at a new 52-week high of $26.66. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 3.7 million shares. Zogenix Inc. (NASDAQ:ZGNX) defies analysts with a current price ($26.57) 0.4% above its avera...
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approx...